Charlotte Schubert

Charlotte Schubert

Seattle, Washington, U.S.

University of Washington’s David Baker Credits Open-Code Rosetta Commons for Protein Design Startup Success

David Baker, director of the University of Washington’s Institute for Protein Design (IPD), emphasizes open code sharing as key to the institute’s success in creating protein design startups. The IPD’s collaborative Rosetta Commons consortium has enabled widespread development of protein design tools, fostering innovation and spinouts in biotech.

Phase Genomics Secures $2.5M to Develop AI Platform for Detecting Cancer Chromosomal Aberrations

Seattle startup Phase Genomics received $2.5 million in funding, including $2 million from the U.S. National Cancer Institute and $500,000 from Washington state's Andy Hill CARE Fund, to advance its AI-driven platform that detects chromosomal aberrations in cancer. The funding supports projects analyzing tumor samples to develop predictive scores for cancers like acute myeloid leukemia and colorectal cancer.

Seattle's Dexter Yard Develops into Major South Lake Union Biotech Cluster with Outpace Bio and Allen Institute

Seattle's Dexter Yard has become a growing biotech and life sciences hub, attracting companies like Outpace Bio and the Allen Institute with 528,000 square feet of new lab and office space. The area, located in South Lake Union, is part of a larger regional expansion of science facilities supported by major real estate developments and significant biotech investment.

Morphimmune, led by ex-Seagen CEO Clay Siegall, merges with Immunome in $125M deal to advance oncology therapies

Biotech startup Morphimmune, led by former Seagen CEO Clay Siegall, is merging with public company Immunome in a $125 million deal backed by private investors, creating a new company focused on oncology therapies headquartered in Seattle. Siegall will lead the merged entity as CEO, president, and chairman, building on his track record in drug development and targeting innovative cancer treatment methods.

AltPep Raises $52.9M to Advance Early Detection and Treatments for Alzheimer’s and Parkinson’s Diseases

AltPep, a University of Washington spinout developing tests and treatments for Alzheimer’s and Parkinson’s, raised $52.9 million in Series B funding to advance clinical trials and regulatory approval for its early detection blood test. The company targets toxic oligomers linked to Alzheimer’s and a related protein in Parkinson’s, aiming to enable early screening and preventive treatment.

Ukrainian-born Ivan Liachko Founded Phase Genomics in 2015 to Advance DNA Sequencing, Earning 2023 GeekWire Startup CEO Finalist Spot

Ukrainian-born scientist Ivan Liachko founded the biotech startup Phase Genomics in 2015, leveraging a DNA sequencing technique developed during his postdoc to support diverse genome projects. The company, now with 26 employees, is recognized for its scientific culture and is a finalist for the 2023 GeekWire Startup CEO of the Year award.

Seattle Startup Aiberry Raises $8M for AI Mental Health Screening Software Using Conversation Analysis

Seattle-area startup Aiberry raised $8 million to develop AI-powered software that screens mental health conditions by analyzing audio, visual, and language data from short conversations. The tool offers an alternative to traditional surveys by providing risk scores and insights via a clinician dashboard, and is compliant with federal health privacy regulations.

Abacus Bioscience Raises $4.4M for Novel Cancer Vaccine Technology Led by Ex-Seagen Executives

Abacus Bioscience, a University of Washington spinout led by former Seattle Genetics veterans, raised $4.4 million to develop a novel cancer vaccine approach targeting tumor antigens to stimulate a strong immune response. Despite historical skepticism about cancer vaccines, Abacus aims to advance a new technology that activates immune cells via antibody fragments linked to tumor antigens.

Seattle-Area Longevity Biomedical to Go Public via SPAC in Q2 2023, Raising $30M with $236M Valuation

Longevity Biomedical, formed by merging Seattle-area startups Cerevast Medical, NovoKera, and Aegeria Soft Tissue, plans to go public via a SPAC merger expected to close in Q2 2023, raising at least $30 million. The combined company targets healthspan extension with treatments for stroke, blindness, and soft-tissue reconstruction, and is valued at $236.2 million.

Seattle Biotech Myosana Raises $5M to Develop Advanced Gene Therapy for Duchenne Muscular Dystrophy

Myosana Therapeutics, a Seattle biotech co-founded by University of Washington researchers, raised $5 million to advance a novel gene therapy candidate targeting Duchenne muscular dystrophy (DMD). The company aims to develop a gene delivery platform that can handle larger DNA segments compared to current standard methods, potentially improving treatment options against DMD.

SafKan Health Raises $8M and Secures FDA Clearance for OtoSet Earwax Removal Device after Viral TikTok Success

Seattle-based SafKan Health has raised $8 million and received FDA clearance for its OtoSet device, which removes earwax through a combination of irrigation and suction and has gained viral attention on TikTok. The device aims to modernize earwax removal by being faster and easier to use than current clinical methods, and has been adopted by hundreds of clinics.

Century Therapeutics Cuts 25% Staff, Closes Seattle and Hamilton Sites, R&D Head Hyam Levitsky to Resign by Jan 31

Century Therapeutics is closing its Seattle hub and cutting 25% of its workforce, including a shutdown of its Hamilton, Ontario location, as it shifts priorities and extends its cash runway to 2026. The company’s president of R&D, Hyam Levitsky, plans to resign by January 31, and Century is de-prioritizing programs for glioblastoma and blood cancers.

Online